Oral Semaglutide in Patients With T2DM
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy and Safety of the Glucagon-Like Peptide-1 Receptor Agonist Oral Semaglutide in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Diabetes Res. Clin. Pract. 2021 Jan 09;[EPub Ahead of Print], J Li, K He, J Ge, C Li, Z JingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.